Profitability
Weight: 20%
F
0
- 5yr Avg ROIC -34.3%
- Operating Margin Trend -385486.62 pp/yr
ALLO
Allogene Therapeutics, Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 4.5 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -52.2%
- 5yr Share-Count CAGR 12.9%
Growth Quality
Weight: 15%
F
0
- Revenue-Growth Years (5) 0/5
Cash Generation
Weight: 15%
F
0
- 5yr FCF Margin -327579.2%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 20%
F
0
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) -176.57x
- Altman Z-Score -4.32
Stability
Weight: 15%
D-
30
- Negative-Revenue Years (5) 3/5
- Piotroski F-Score 2
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.1 of 2 gurus held; 1 added; 1 full exit.
- Holders
- 1 -1
- Avg Δ position
- +70.4%
- New buys
- 0
- Full exits
- 1